FIELD: medicine; pharmaceuticals; food industry.
SUBSTANCE: invention relates to a combined therapeutic nutrition product for the treatment of TK2-associated mitochondrial myopathy. A combined therapeutic nutritional product for the treatment of TK2-associated mitochondrial myopathy with two separate formulations including thymidine and deoxycytidine, respectively, where composition 1 contains the following, in mg:
composition 2 contains the following, in mg:
EFFECT: above-described use of thymidine and deoxycytidine with maltodextrin as a combined therapeutic nutritional product is effective for the treatment of TK2-associated mitochondrial myopathy, ensures the absence of adverse events and undesirable reactions, such as deviations from the norm in biochemical parameters of the liver and kidneys; no diarrhea; the presence of statistically significant differences in the average score of the HFMSE scale, reflecting gross motor skills; statistically significant differences in the average score of all indicators of the HINE-2 Scale; statistically significant differences in the average score of the MRC Scale, which reflects muscle strength; differences in the average need for respiratory support (NIV) before and after use of the product, compared with the use of deoxynucleosides in the form of chemicals; the product also has good organoleptic properties and a pleasant taste.
1 cl, 2 dwg, 15 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF THYMIDINE AND DEOXYCYTIDINE AS A COMBINED NUTRITIONAL PRODUCT FOR THE TREATMENT OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY | 2023 |
|
RU2811282C1 |
METHOD OF CORRECTING FUNCTIONAL STATE OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY | 2023 |
|
RU2811280C1 |
DEOXYNUCLEOSIDE THERAPY OF DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | 2016 |
|
RU2721492C2 |
DEOXYNUCLEOSIDE THERAPY OF DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | 2016 |
|
RU2827432C2 |
METHOD OF TREATING CONGENITAL STRUCTURAL MYOPATHIES AND CONGENITAL MUSCULAR DYSTROPHIES BY CORRECTION OF SECONDARY MITOCHONDRIAL CHANGES | 2008 |
|
RU2400221C2 |
METHOD FOR PREDICTION OF DEVELOPING PROGRESSIVE CLINICAL COURSE OF MULTIPLE SCLEROSIS | 2024 |
|
RU2825506C1 |
TREATMENT OF MITOCHONDRIAL DISEASES | 2016 |
|
RU2745611C2 |
METHOD FOR PREDICTING THE RISK OF DEATH WITHIN 6 MONTHS AFTER SUFFERING A NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2766302C1 |
METHOD FOR PREDICTING OUTCOME OF ACUTE PERIOD OF ISCHEMIC STROKE ASSOCIATED WITH COVID-19 | 2021 |
|
RU2763834C1 |
METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
Authors
Dates
2024-01-17—Published
2023-10-19—Filed